Optimal- versus standard-antiplatelet therapy for patients with high on-treatment platelet reactivity: 2-year outcomes of the multicenter, randomized Optimal antiPlatelet Therapy (OPT) trial
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.